Response-based chemotherapy and involved field radiation for intermediate stage Hodgkin disease. A GISL/NHLSG trial

被引：0
|
作者：
Iannitto, E. [1 ]
Minardi, V. [1 ]
Gobbi, P. G. [2 ]
Luminari, S. [3 ]
Calvaruso, G. [1 ]
Stelitano, C. [4 ]
Baldini, L. [5 ]
Merli [6 ]
Petrini, M. [7 ]
Marcheselli, L. [3 ]
Mammi, C. [3 ]
De Cantis, S. [1 ]
Abbadessa, V [1 ]
Federico, M. [3 ]
机构：
[1] Univ Palermo, I-90133 Palermo, Italy
[2] Univ Pavia, I-27100 Pavia, Italy
[3] Univ Modena & Reggio Emilia, Dept Hematol & Oncol, Modena, Italy
[4] Osped Bianchi Melacrino Morelli, Reggio Di Calabria, Italy
[5] Univ Milan, Dipartimento Ematol, I-20122 Milan, Italy
[6] Osped SM Nuova, Reggio Emilia, Italy
[7] Univ Pisa, I-56100 Pisa, Italy
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2007年 / 92卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1 / 1
页数：1
相关论文
共 50 条
  • [21] End results of a prospective clinical trial with VAMP and low-dose, involved-field radiation for pediatric patients with favorable, early-stage Hodgkin's disease
    Donaldson, S
    Tarbell, N
    Weinstein, H
    Link, M
    Kun, L
    Billett, A
    Marcus, K
    Hurwitz, C
    Young, J
    Brain, S
    Hudson, M
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 63 (02): : S21 - S21
  • [22] Dose-Intensive Response-Based Chemotherapy and Radiation Therapy for Children and Adolescents With Newly Diagnosed Intermediate-Risk Hodgkin Lymphoma: A Report From the Children's Oncology Group Study AHOD0031
    Friedman, Debra L.
    Chen, Lu
    Wolden, Suzanne
    Buxton, Allen
    McCarten, Kathleen
    FitzGerald, Thomas J.
    Kessel, Sandra
    De Alarcon, Pedro A.
    Chen, Allen R.
    Kobrinsky, Nathan
    Ehrlich, Peter
    Hutchison, Robert E.
    Constine, Louis S.
    Schwartz, Cindy L.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (32) : 3651 - 3658
  • [23] RESULTS OF US INTERGROUP TRIAL OF RESPONSE-ADAPTED CHEMOTHERAPY OR CHEMOTHERAPY/RADIATION THERAPY BASED ON PET FOR NON-BULKY STAGE I AND II HODGKIN LYMPHOMA (CALGB/ALLIANCE 50604)
    Straus, D.
    Pitcher, B.
    Kostakoglu, L.
    Grecula, J. C.
    Hsi, E. D.
    Schoder, H.
    Jung, S. -H.
    Popplewell, L.
    Chang, J. E.
    Moskowitz, C.
    Wagner-Johnson, N.
    Leonard, J.
    Friedberg, J. W.
    Kahl, B. S.
    Cheson, B. D.
    Bartlett, N. L.
    HAEMATOLOGICA, 2016, 101 : 13 - 13
  • [24] Efficacy of vinblastine, bleomycin, methotrexate (VBM) combination chemotherapy with involved field radiotherapy in early stage (I-IIA) Hodgkin disease patients
    Martinelli, G
    Cocorocchio, E
    Saletti, PC
    Orecchia, R
    Bernier, J
    Tradati, N
    Santoro, P
    Robertson, C
    Peccatori, FA
    Zucca, E
    Cavalli, F
    LEUKEMIA & LYMPHOMA, 2003, 44 (11) : 1919 - 1923
  • [25] Autotransplantation for relapsed or refractory Hodgkin disease followed by post-transplant involved-field radiation and four cycles of consolidation chemotherapy.
    Rapoport, AP
    Badros, A
    Hakimian, R
    Mannuel, H
    Meisenberg, B
    Akpek, G
    Takebe, N
    Fenton, R
    Heyman, M
    Ruehle, K
    George, B
    Natt, S
    Ratterree, B
    Withers, T
    Guo, CF
    BLOOD, 2003, 102 (11) : 736A - 736A
  • [26] A prospective trial of involved field radiation (IFRT) plus chemotherapy vs extended field (EFRT) radiation for favorable Hodgkin's disease (HD): Long-term follow-up and implications for current combined modality therapy
    Horning, S. J.
    Hoppe, R. T.
    Advani, R. H.
    Breslin, S.
    McCormick, E.
    Allen, J.
    Hancock, S. L.
    Rosenberg, S. A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 53 - 53
  • [27] Efficacy of abbreviated Stanford V chemotherapy and involved-field radiotherapy in early-stage Hodgkin lymphoma: mature results of the G4 trial
    Advani, R. H.
    Hoppe, R. T.
    Baer, D.
    Mason, J.
    Warnke, R.
    Allen, J.
    Daadi, S.
    Rosenberg, S. A.
    Horning, S. J.
    ANNALS OF ONCOLOGY, 2013, 24 (04) : 1044 - 1048
  • [28] Involved field radiotherapy in partial response after doxorubicin-based chemotherapy for advanced aggressive non-Hodgkin's lymphoma
    Moser, E
    Noordijk, E
    Kluin-Nelemans, J
    ANNALS OF ONCOLOGY, 2005, 16 : 97 - 97
  • [29] Lung function and serum levels of different cytokines in patients treated with intermediate-high dose chemotherapy and radiotherapy involved fields for advanced stage Hodgkin's disease
    Di Russo, A
    Villani, F
    Soncini, F
    Catania, AF
    Viola, G
    Vismara, C
    Viviani, S
    Bonfante, V
    TUMORI, 2001, 87 (04) : S121 - S121
  • [30] Initial Results of US Intergroup Trial of Response-Adapted Chemotherapy or Chemotherapy/Radiation Therapy Based on PET for Non-Bulky Stage I and II Hodgkin Lymphoma (HL) (CALGB/Alliance 50604)
    Straus, David J.
    Pitcher, Brandelyn
    Kostakoglu, Lale
    Grecula, John C.
    Hsi, Eric D.
    Schoder, Heiko
    Jung, Sin-Ho
    Popplewell, Leslie L.
    Chang, Julie E.
    Moskowitz, Craig H.
    Wagner-Johnson, Nina
    Leonard, John P.
    Friedberg, Jonathan W.
    Kahl, Brad S.
    Cheson, Bruce D.
    Bartlett, Nancy L.
    BLOOD, 2015, 126 (23)
12345